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Abstract
The tumor microenvironment supplies proinﬂammatory cyto-
kines favoring a permissive milieu for cancer cell growth and
invasive behavior. Here we show how breast cancer progression is
facilitated by IL4 secretedby adipose tissue and estrogen receptor–
positive and triple-negative breast cancer cell types. Blocking
autocrine and paracrine IL4 signaling with the IL4Ra antagonist
IL4DM compromised breast cancer cell proliferation, invasion,
and tumor growth by downregulating MAPK pathway activity.
IL4DM reduced numbers of CD44þ/CD24 cancer stem-like cells
and elevated expression of the dual speciﬁcity phosphatase
DUSP4by inhibitingNF-kB. Enforced expression ofDUSP4drove
conversion of metastatic cells to nonmetastatic cells. Mechanisti-
cally, RNAi-mediated attenuationofDUSP4activated theERKand
p38MAPKpathways, increased stem-like properties, and spawned
metastatic capacity. Targeting IL4 signaling sensitized breast
cancer cells to anticancer therapy and strengthened immune
responses by enhancing the number of IFNg-positive CTLs. Our
results showed the role of IL4 in promoting breast cancer aggres-
siveness and how its targeting may improve the efﬁcacy of current
therapies. Cancer Res; 77(12); 3268–79. 2017 AACR.
Introduction
Despite the advent of efﬁcacious treatment of primary breast
cancer lesions, metastatic disease is poorly sensitive to the com-
mon therapeutic regimens (1).
Adipose tissue is the most abundant constituent of the breast
cancer microenvironment and is mainly composed of mature
adipocytes, preadipocytes, and adipose-derived stem cells (ADSC;
ref. 2). Obesity and overweight have recently been suggested as
beingmeaningful risk factors for the development of breast cancer
and its therapy resistance (3). Indeed, compelling evidence shows
that paracrine signals, provided by the adipose tissue and sur-
rounding cancer cells, contribute to tumorigenesis and cancer
progression (2, 4). Secreted protumorigenic cytokines and hor-
mones feed breast cancer cells regardless of their hormone status
and are also responsible for the acquisition of an aggressive cell
phenotype (5).
Furthermore, we have identiﬁed autocrine and paracrine
production of IL4 as a survival signal and tool to protect
colorectal cancer cells from anticancer therapy, through the
upregulation of antiapoptotic molecules (6, 7). Indeed, IL4 is a
pleiotropic cytokine secreted by ﬁbroblasts, immune, adipose,
and a wide range of epithelial cells, including breast cancer cells
(8). IL4 cognate receptors comprise two types: (i) type I IL4R
(IL4RI) and (ii) type II IL4R (IL4RII). The ﬁrst is mainly present
on immune cells and characterized by the heterodimerization
of the IL4Ra and the common g-chain subunits. IL4RII, on the
other hand, is present on nonhematopoietic cells and com-
posed of IL4Ra and the IL13Ra1 subunits. IL4RII is expressed
on the surface of many cancer cells and lacks intrinsic kinase
activity, thus it requires further associated kinases for the
initiation of signal transduction (8). Upon binding of IL4,
the tyrosine kinases Jak1/2 and Tyk2 are indeed recruited on
the transmembrane domain of IL4RII and mediate its phos-
phorylation, leading to the activation of PI3K/AKT, MAPK, and
Jak/STAT6 downstream pathways (8).
In breast cancer, the secretion of the protumorigenic cytokines,
IL6 and IL8, is controlled by the dual speciﬁcity phosphatase 4
(DUSP4; ref. 9). In physiologic conditions, the transcription of
DUSP4 is MEK-dependent and its expression in turn suppresses
ERK, along with p38, JNK1, NF-kB, and Rb (9–12), ensuring a
proper negative feedback control of cellular proliferative stimuli.
DUSP4 is differentially expressed among luminal andbasal breast
cancers. Speciﬁcally, the most aggressive tumors hold DUSP4
under-expression, due to methylation events or genomic loss
(9, 10).
It has been clearly demonstrated that a subpopulation of cancer
cells, named tumor-initiating cells (TIC), is endowed with the
capability of self-renewal and tumor initiation (13–16). Indeed,
this cell compartment is refractory to the common anticancer
drugs and responsible for recurrence (13–16).
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An inﬂammatory microenvironment has been shown to favor
the maintenance of the breast TICs and their invasive behavior
(17, 18). However, insufﬁcient data are available on the mechan-
isms regulating this phenomenon. Recently, it has been demon-
strated that, in a syngeneic breast cancer mouse model, the IL4/
IL4R interaction promotes metastatic spreading by activating the
MAPK pathway (19).
Taken together, these ﬁndings suggest that IL4may conceivably
play a role in the progression of breast cancer and resistance to
standard therapeutic regimens driven by TICs. In this study, we
establish for the ﬁrst time the molecular mechanisms elicited by
IL4, which augment proliferation and invasiveness of breast
cancer sphere cells (BCSC), notoriously largely composed of TICs
(15). Blocking autocrine and paracrine IL4 signaling via the
attenuation of the MAPK pathway, counteracts the protumori-
genic effect of all the proinﬂammatory cytokines released by
ADSCs. Moreover, we unveil that IL4 acts through NF-kB to lower
DUSP4 expression levels.
Here, we emphasize the role of IL4 in themetastatic potential of
BCSCs and its neutralization as a useful strategy for therapeutic
intervention.
Materials and Methods
Tissue collection
Breast cancer tissues were collected at the Department of
Surgical, Oncological and Stomatological Sciences (University
of Palermo, Palermo, Italy), in accordance with the ethical stan-
dards of the Institutional Committee onHumanExperimentation
and their molecular subtypes. Breast cancer characterization
was established using the following IHC markers (20): ERþ,
PRþ/, HER2, Ki67low (luminal A); ERþ, PRþ/, HER2, Ki67high
or ERþ, PRþ/, HER2þ (luminal B); ER, PR, HER2þ (HER2
ampliﬁed); ER, PR, HER2 (triple negative breast cancer,
TNBC; Table 1). Cancer staging was determined according to the
7th Edition AJCC classiﬁcation of malignant tumors.
Isolation and culture of cancer cells
Breast cancer tissue was mechanically and enzymatically
digested using collagenase (1.5 mg/mL; Gibco) and hyaluron-
idase (20 mg/mL; Sigma Aldrich) in DMEM and shaken for 1
hour at 37C. The recovered cell suspension was plated in
ultra-low attachment ﬂasks in serum-free medium (SFM) sup-
plemented with basic ﬁbroblast growth factor (bFGF; 10
ng/mL; PeproTech) and EGF (20 ng/mL; PeproTech), as pre-
viously described (21, 22). SFM allows breast cancer cells to
propagate as sphere structures, which are enriched in cells that
harbor stem-like and tumor-initiating properties (6, 13, 15).
We used ERþ-BCSCs derived from luminal B patients #4 and
#18 and TN-BCSCs, derived from TNBC patients #10 and #30
(Table 1) for all the experiments performed. BCSCs and their
relative tumor tissues were authenticated using a highly infor-
mative short tandem repeat (STR) system (GlobalFiler STR Kit;
Applied Biosystems) and then sequenced using the ABIPRISM
3130 genetic analyzer (Applied Biosystems). CD90 staining
was used to exclude the presence of stromal cells within the
ERþ- and TN-BCSC compartment. Human ADSCs were pur-
chased from STEMPRO and cultured for less than six passages
according to manufacturer's instructions. MCF7 cell line was
purchased from CLS cell line service in July 2013, authenti-
cated from the cell bank by DNA proﬁling (STR analysis), and
maintained in 10% FBS DMEM. Cells, expanded for two
passages after receipt, were then frozen and used within 6
months after thawing. SUM159 cell line was kindly provided
by Prof. Max Wicha (University of Michigan, Ann Arbor, MI)
and authenticated in our laboratory by STR as described above.
SUM159 cells were cultured in Ham F-12, 5% FBS, hydrocor-
tisone (1 mg/mL; Sigma), insulin (5 mg/mL; Sigma-Aldrich).
Cells were routinely tested for mycoplasma infection with
MycoAlert PLUS Mycoplasma Detection Kit (Lonza), revealed
using Inﬁnite F500 (Tecan).
BothBCSCs and establishedbreast cancer cell lineswere exposed
to ADSC conditioned medium (ADSC-CM), IL4 (20 ng/mL;
PeproTech), and the IL4Ra antagonist (IL4DM; 15 mg/mL), kindly
donated by Apogenix. IL4DM was administered for a total of 72
hours. All treatments were replenished every 48 hours.
Withaferin A (Wit A, 2 mmol/L, Tocris) and 5-aminosalicylic
acid (5-ASA, 26 mmol/L; Sigma-Aldrich) were used as NF-kB
inhibitors and added 1hour and 30minutes before IL4 treatment,
respectively.
For the cell viability assay, BCSCswere exposed to fulvestrant (1
mmol/L; Selleckchem), docetaxel (100 nmol/L; Selleckchem) or
BKM120 (5 mmol/L; Selleckchem). BCSCs were exposed to IFNg
(100 ng/mL; Novus Biologicals), as positive control for PD-L1
expression, for 4 and 24 hours.
To evaluate the expression of PD-1 or IFNg in gated CD8þ T
cells, 5 105 PBMCs/mLwere activated (Activated) for 4 days in
24-well plates coated with puriﬁed anti-human CD3e (OKT3,
IgG2a; Biolegend), anti-human CD28 (CD28.2, IgG1k; Biole-
gend), and in presence of human rIL2 (100 IU/mL Proleukin;
Novartis Pharmaceuticals) in 10% FBS RPMI. Activated
cells were then treated, for additional 4 days, with medium
(medium), IL4, IL4DM alone, or in combination with IL4
(IL4þIL4DM). Prior ﬂow cytometry analysis, for the intracel-
lular staining of cytokines, untreated and treated activated cells
were cultured in presence of PMA (20 ng/mL; BD Biosciences)
and ionomycin (1 mmol/L; BD Biosciences) for 4 hours and for
the last 3 hours in combination with monensin (2 mmol/L;
Sigma-Aldrich), for blocking cellular protein transport.
CM production and Luminex cytokine quantiﬁcation
CM from ADSCs (ADSCs-CM), ERþ-BCSCs (ERþ-CM) and TN-
BCSCs (TN-CM) were obtained from cells plated at 70% conﬂu-
ence and cultured in SFM for 48 hours. CMwas ﬁltered through a
0.22-mm ﬁlter to eliminate cell debris.
Table 1. Description of breast cancer clinical features
Patient Grading ER PR
HER2
ampliﬁcation Ki67 Clinical receptor subtype
Sphere
formation
Xenograft
formation
#4 G2 þ þ Yes >10% Luminal B Yes Yes
#10 G2   No >10% TNBC Yes Yes
#18 G2 þ þ Yes >10% Luminal B Yes Yes
#30 G3   No >10% TNBC Yes Yes
Abbreviations: ER, estrogen receptor; PR, progesterone receptor.
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Quantiﬁcation of cytokine production was assessed by using
multiplex Bio-Plex Pro Assays (Human Cytokine 21 and 27-plex
Assay; Bio-Rad). Raw data (mean ﬂuorescence intensity) were
analyzed by Bio-Plex Software (Bio-Rad).
Cell motility and invasion assay
A total of 1  103 BCSCs were plated into 6-well attachment
plates in DMEM with 10% FBS to allow cell attachment. The
spreading of cells, which were treated withmedium alone, ADSC-
CM, or IL4 in presence of 5% FBS, was determined by phase
contrast microscopy at 12 hours.
A total of 2 103 breast cancer cells, treated with IL4DM for 24
hours and subsequently exposed to ADSCs-CM or IL4 for another
48 hours in SFM, were plated onto growth factor–reduced matri-
gel (BD Biosciences)-coated transwell of 8-mm pore size. SFM in
presence of 10% human serum AB was used as a chemoattractant
in the bottom part of the chamber (600 mL/well). Cells invading
Matrigel were monitored and counted using an optical micro-
scope for up to 48 hours.
Cell viability
Cell viability was performed using the CellTiter-Glo Lumines-
cent Cell Viability Assay Kit (Promega) according to the manu-
facturer's instruction. Cell proliferation was assessed using Cell-
Titer 96 AQueous One Solution cell proliferation assay (MTS)
according to the manufacturer's instruction. Detection of both
luminescence and absorbance was measured by using Inﬁnite
F500 (Tecan).
Stem cell frequency and colony-forming efﬁciency
BCSCs were plated at a concentration of a single cell per well.
Wells containing more than three cells were excluded. The stem
cell frequency was statistically evaluated after 3 weeks by using
ELDA analysis program (23). For the colony-forming assay, 500
dissociated BCSCs were mixed with 0.3% agarose (SeaPlaque
Agarose Lonza) in SFM and seeded onto a layer of 0.4%
agarose. After 20 days, colonies were stained with 0.01% crystal
violet in 1%methanol. Colonies were ﬁrst distinguished on the
basis of their size: micro < 30 mm; small 30–60 mm; medium
60–90 mm; and large >90 mm and then counted using ImageJ
software.
Animals and tumor models
Mice experiments were performed according to the ARRIVE
and animal care committee guidelines of the University of
Palermo. A total of 4  103 BCSCs, treated with medium alone
or IL4 for 24 hours, were suspended in 100 mL of SFM 1:1
Matrigel (BD Biosciences) and injected subcutaneously into
6-week-old female NOD/SCID mice (Charles River Laborato-
ries). After 1 week, mice were intraperitoneally treated with
vehicle (PBS) or IL4DM (3 mg/kg) 5 days/week for 10 weeks
(6, 24). One week after the end of treatment, at 12 weeks, mice
were sacriﬁced following IACUC guidelines and tumor xeno-
grafts were collected. Tumor growth was monitored weekly
with an electronic caliper. Tumor volume was calculated using
the formula: largest diameter  (smallest diameter)2  p/6. For
tail vein experiments, 1.5  105 luciferase (LUC)-transduced
BCSCs (Supplementary Information) were suspended in 30 mL
of PBS and injected into 6-week-old female NOD/SCID mice.
After injection of VivoGlo Luciferin (150 mg/kg; Promega), in
vivo cell spreading was monitored by the detection of biolu-
minescence intensity using a Photon IMAGER (Biospace Lab),
for up to 9 weeks. The photon count (photons/s/sr, photons per
second per steradian), emitted by mice metastasis, was calcu-
lated by using M3 Vision (Biospace Lab). Mice were sacriﬁced
when lesions reached 4  103 photons/s/sr, corresponding to a
0.5 cm2 tumor area, and liver and lungs were analyzed ex vivo
to detect metastasis formation.
Flow cytometry
ERþ- and TN-BCSCs were washed twice in PBS and stained at
4C with puriﬁed CD44-PE (G44-26, mouse IgG2b; BD Bio-
sciences), CD24-APC (ML5, mouse IgG2a; R&D Systems),
CD10-APC (97C5, mouse IgG1; Miltenyi Biotec), MUC1-PE
(604804, mouse IgG2b; R&D Systems), CD49f-APC (GoH3, rat
IgG2a; Miltenyi Biotec), EPCAM-PerCP (EBA-1, mouse IgG1;
BD Biosciences), or CD90-PE-CF594 (5E10, IgG1k; BD Bio-
sciences) antibodies or corresponding IMC CD14-PE (MfP9,
IgG2b; BD Biosciences), CD4-APC (11830, IgG2a; R&D Sys-
tems), CD4-APC (REA623, IgG1; Miltenyi Biotec), CD8-PE
(37006, IgG2b; R&D Systems), CD3-APC (BW264/56, IgG2a;
Miltenyi Biotec), CD3-PERCP (SP34-2, IgG1; BD Biosciences),
CD3-PE-CF594 (UCHT1, IgG1k; BD Biosciences). Dead cells
were excluded on the basis of light scatter and the uptake of 7-
AAD (0.25 mg/L  106 cells; BD Biosciences) detected in FL3
channel. Single cells were gated in FSC-A versus FSC-H dot
plots. Samples were analyzed by FACSCanto II (BD Bios-
ciences) or Accuri C6 (BD Biosciences) ﬂow cytometer and
data analyzed using FlowJo software (Tree Star).
PBMCs were incubated on ice with FcR blocking reagent
(Miltenyi Biotec) and stained with CD3-PeCy7 (UCHT1,
mouse IgG1k; Biolegend), CD8-PE (RPA-T8, mouse IgG1k;
BD Biosciences), IFNg-APC (B27, mouse IgG1k; BD Bios-
ciences), PD-1-FITC (EH12.2H7, mouse IgG1k; Biolegend)
antibodies or corresponding isotype matched controls (IMC),
speciﬁcally APC mouse IgG1k (MOPC-21; BD Biosciences)
and FITC mouse IgG1k (MOPC-21; Biolegend). For intracel-
lular staining, cells were previously subjected to Cytoﬁx/
Cytoperm protocol following the manufacturer's instructions
(BD Biosciences).
Western blot analysis
Cells were washed in ice-cold PBS and suspended in TPER
Reagent (Pierce) in presence of NaCl (300 mmol/L; Sigma
Aldrich), sodium orthovanadate (1 mmol/L; Sigma Aldrich),
pefabloc (2 mmol/L; Roche), and proteinase inhibitor cocktail
(5 mg/mL; Sigma Aldrich). Extracted proteins were loaded, sep-
arated by SDS-PAGE, and blotted onto nitrocellulosemembranes
(Hybond-C Extra, nitrocellulose; Amersham Biosciences). Mem-
branes were blocked in 0.1% Tween 20 and 5% non-fat dry milk
for 1 hour at room temperature and then exposed to DUSP4
(D9A5, rabbit IgG, Cell Signaling Technology), P-MEK (41G9,
rabbit IgG, Cell Signaling Technology), MEK (rabbit polyclonal,
Cell Signaling Technology), P-ERK (E-4,mouse IgG2a, Santa Cruz
Biotechnology), ERK (rabbit polyclonal, Santa Cruz Biotechnol-
ogy), RAS (27H5, rabbit IgG, Cell Signaling Technology), P-NF-
kB (T.849.2, rabbit IgG, Thermo Fisher Scientiﬁc), NF-kB
(112A1021, mouse IgG1k; Thermo Fisher Scientiﬁc), P-P38
(D3F9, rabbit IgG; CST), P38 (rabbit polyclonal; Cell Signaling
Technology), IL4Ra (25463.111, mouse IgG2a; R&D Systems),
IL13Ra2 (goat polyclonal; R&D Systems), P-STAT6 (rabbit poly-
clonal; Cell Signaling Technology), STAT6 (rabbit polyclonal; Cell
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Signaling Technology), PD-L1 (E1L3N, rabbit IgG; Cell Signaling
Technology), or b-actin (8H10D10, mouse IgG2b; Cell Signaling
Technology) antibody. Primary antibodies were revealed using
anti-mouse or anti-rabbit HRP–conjugated (goat IgG; Thermo
Fisher Scientiﬁc) and detected by a chemiluminescence imager
(GE Healthcare).
Statistical analysis
Kaplan–Meier curves of relapse-free survival based on the gene
expression ratio of IL4/DUSP4 in breast cancer patients were
obtained by interrogating the PROGgeneV2 - Pan Cancer Prog-
nostics Database-GSE10893-GPL887. Statistical analysis was cal-
culated using ANOVA with Bonferroni post test. Signiﬁcance was
indicated as P values.
Results
ADSC-CM and IL4 promote expansion of BCSCs
The breast cancer microenvironment is abundantly composed
of adipose tissue that constitutes a reservoir of protumorigenic
molecules (25, 26). In the attempt to identify the main contrib-
utor to breast cancer cells expansion, we examined the compo-
sition of the CM from ADSCs (ADSCs-CM) as well as from ERþ-
and TN-BCSCs (ERþ-CM and TN-CM, respectively). Several stud-
ies demonstrate that ADSCs promote proliferation and invasive
capacity in breast cancer cells (27) and, interestingly, the main-
tenance of the breast TIC pool (28). Moreover, the use of ADSCs
overcomes the difﬁculties experienced in the isolation and long-
term culture of mature adipocytes from adipose tissue (4). ERþ-
and TN-BCSCs, enriched with cells having stem-like properties,
were obtained from surgical resection of breast cancers. ERþ-
BCSCs were derived from patient #4 and #18, whereas TN-BCSCs
from patient #10 and #30 (see Materials and Methods and Table
1), as described previously (22). ERþ cells were positive forMUC1
and EPCAM, and expressed low levels of CD49f, whereas TN cells
displayed epithelial-to-mesenchymal transition (EMT) markers
such as CD10, CD49f, and VIMENTIN (Supplementary Fig. S1A
and S1B).
Exploring the levels of a panel of cytokines across the CMs of
ADSCs and ERþ- and TN-BCSCs, we detected a higher secretion
of proinﬂammatory and protumorigenic cytokines in CMs of
ADSCs and TN-BCSCs. These data suggest that TN-, as opposed
to ERþ-BCSCs, support the generation of an inﬂammatory
microenvironment, linked to enhanced tumorigenic features
(Fig. 1A and B).
In the past, we have reported that IL4 is secreted by primary
cancer cells isolated from breast cancer specimens (29) and
constitutes an autocrine and paracrine prosurvival signal for
breast and colorectal TICs (6, 7, 29). In ADSCs-CM, the secreted
IL4 levels were comparable with those in the TN-CM and greater
than in the ERþ-CM (Fig. 1A). Likewise, ERþMCF7 cells expressed
signiﬁcant lower IL4 mRNA levels than TN SUM159 established
cell line (40-fold difference; Supplementary Fig. S1C). Of note,
the exposure to ADSCs-CM, for 6 hours, boosted the IL4 mRNA
levels of ERþ-BCSCs and MCF7 cells (Supplementary Fig. S1D).
Although the ERþ-BCSCs morphologic shape was not affected
by the exposure toADSCs-CMor IL4 (data not shown), TN-BCSCs
acquired elongated protrusions early on, expanding in all direc-
tions (Fig. 1C). Thus, this phenomenon indicates a susceptibility
of TN-BCSCs to acquire a migratory phenotype upon microen-
vironmental stimuli.
We also assessed the capability of breast cancer cells to expand
in response to ADSCs-CM and IL4 stimuli and found a stepwise
increase in the proliferation of both ERþ- and TN-BCSCs aswell as
bulk MCF7 and SUM159 cells (Fig. 1D and Supplementary Fig.
S1E). In presence of ADSCs-CM and IL4, stem cell frequency
resulted in a 2- to 3-fold increase of in ERþ- and TN-BCSCs (Fig.
1E), and was paralleled by a signiﬁcant increase in the formation
of colonies (Fig. 1F) large in size (>90mm; Fig. 1G; Supplementary
Fig. S1F).
ADSCs boost BCSCs proliferation and invasion in
an IL4-dependent manner
To investigate whether IL4 is the main player within ADSCs-
secreted cytokines that enhance the aggressiveness of breast cancer
cells, we evaluated its receptor expression on ERþ- and TN-BCSCs.
Both BCSC subtypes displayed IL4Ra along with IL13Ra2, a
receptor inhibitor of IL13 signaling (Supplementary Fig. S2A and
S2B; ref. 30).
Accordingly, we interfered with IL4 ligand/receptor interaction
by using an IL4Ra antagonist, which consists of a double mutant
IL4 (IL4DM) generated by the replacement of two amino acids
(R121D and Y124D; refs. 24, 31). This molecule binds to IL4Ra
and IL13Ra1 with the same afﬁnity as the wild-type IL4 but lacks
the agonistic activity (Supplementary Fig. S2C). Because the in
vitro exposure to IL4DM for 72 hours impaired the proliferation of
ERþ- and TN-BCSCs, MCF7, and SUM159 cells (Fig. 2A; Supple-
mentary Fig. S2D),we sought to explorewhether IL4 targetingwas
necessary and sufﬁcient to limit the effect of the ADSCs-CM.
Both ADSCs-CM and IL4 strongly increased the formation of
colonies in the 3D culture (Fig. 2B), which highlights that the
effect of other paracrine cytokines, including IL13, is only partial.
IL4DMwas not only able to affect the ability to form colonies (Fig.
2B), but also to impair the invasive potential of ERþ- and TN-
BCSCs and of the established cell linesMCF7 and SUM159,which
counteracted the effect of both IL4 and ADSCs-CM (Fig. 2C;
Supplementary Fig. S2E).
We found that BCSCs, pretreated with medium or IL4 and
subcutaneously injected into mice, delayed the tumor outgrowth
when IL4DMwas intraperitoneally administered (Fig. 2D; ref. 6).
These ﬁndings suggest that IL4DMdelays the in vivo growth rate of
BCSCs.
IL4DM inhibits MAPK pathway activation, upregulates DUSP4
expression, and sensitizes to anticancer therapy
We wondered whether the administration of IL4DM could
be implicated in the modiﬁcation of the CD44þ/CD24
phenotype of breast TICs with a mesenchymal-like state
(16). In TN-BCSCs, CD24 expression increased in response
to IL4DM, suggesting that tumor cells with stem-like features
may transit between a mesenchymal-like and a less aggressive
epithelial-like phenotype (Fig. 3A; Supplementary Fig. S3A;
refs. 9, 32). We did not notice any signiﬁcant change in CD24
expression in the exiguous compartment of CD24 cell frac-
tion present in the ERþ-BCSCs, following exposure to IL4DM
(data not shown).
It has recently been demonstrated that the depletion of CD44þ/
CD24 population is determined by the exogenous expression of
DUSP4 (9). DUSP4 is highly expressed in ERþ-BCSCs, whereas it
was barely detectable in the TNBC subtype. ERþ- and TN-BCSCs,
in presence of IL4DM and ADSCs-CM, gradually increased the
expression of DUSP4 for up to 24 hours (Fig. 3B).
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Figure 1.
ADSC-CM and IL4 enforce the motility and proliferation of BCSCs. A, Cytokines production of CMs derived from ADSCs, ERþ-BCSCs, and TN-BCSCs after 48 hours.
B, Schematic model of paracrine and autocrine signals occurring in breast cancer cells. C, Representative phase contrast analysis of TN-BCSCs (pt #30) in
presence of the indicated treatment and cultured in adherence for 12 hours. Arrows, cells protrusions. Scale bars, 20 mm. D, Cell proliferation analysis of ERþ-BCSCs
and TN-BCSCs treated with medium, ADSCs-CM, or IL4. E, Stem cell frequency of ERþ-BCSCs and TN-BCSCs treated as in D at 21 days. F, Fold increase of
colony number in ERþ-BCSCs and TN-BCSCs treated as in E. G, Colony-forming efﬁciency of cells treated as indicated. Data are expressed as mean  SD of three
independent experiments using two different ERþ-BCSC (pt #4 and pt #18) and two TN-BCSC (pt #10 and pt #30) lines.  , P < 0.05;  , P < 0.01;  , P < 0.001.
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It was reported that the MAPK pathway activity, including in
breast cancer, is partially modulated by DUSP4 (9–12). We
hypothesized that the effect of IL4DM in impairing prolifera-
tion and invasive potential of BCSCs could be due to the
DUSP4-mediated downregulation of MAPK pathway. IL4DM
decreased the activity of MEK, ERK, and RAS, at 45 minutes and
24 hours (Fig. 3C), even in presence of ADSCs-CM and IL4 in
both ERþ- and TN-BCSCs (Fig. 3D and E; Supplementary Fig.
S3B–S3D). In ERþ-BCSCs, which retain high levels of DUSP4,
IL4DM slightly augmented its levels in the absence or presence
of ADSCs-CM or IL4 (Fig. 3C–E). Similarly, IL4DM prompted
DUSP4 expression in MCF7 and SUM159 cells (Supplementary
Fig. S3E). Although IL4DM boosted DUSP4 expression in TN-
BCSCs (Fig. 3C), this effect was weaker in presence of IL4 and
ADSCs-CM (Fig. 3D and E; Supplementary Fig. S3B–S3D). NF-
kB has been reported to be modulated by IL4 treatment in B
lymphocytes (33) and to promote the expansion of breast TICs,
which contribute to cancer progression (34, 35). To understand
how the IL4 signaling blockade is capable of modulating
expression levels of DUSP4, we analyzed the activation of
NF-kB. The phosphorylation of NF-kB was enhanced by IL4
exposure of both ERþ- and TN-BCSCs, whereas its expression
levels were barely present in ERþ-BCSCs and potently lowered
in TN-BCSCs by the addiction of IL4DM to the cell culture (Fig.
3F; Supplementary Fig. S3F). Withaferin A (Wit A), which
selectively inhibits IKKb (36, 37), overcame the effects of IL4,
reducing the NF-kB activation to a greater extent in TN-BCSCs
(Fig. 3G; Supplementary Fig. S3G). Wit A restored in ERþ- and
upregulated in TN-BCSCs the DUSP4 expression levels in the
presence of IL4 (Fig. 3H). 5-Aminosalicylic acid (5-ASA),
another NF-kB inhibitor (38), behaved like Wit A in boosting
the expression of DUSP4 in both ERþ- and TN-BCSCs (Sup-
plementary Fig. S3H).
Because IL4 blockade circumvents the resistance to conven-
tional antitumor treatment (6, 7), we aimed to couple the inhi-
bition of IL4 with conventional therapies used in breast cancer
management. In this context, several clinical trials are evaluating
the effectiveness of standard therapy in combination with PI3K
Figure 2.
IL4 promotes an invasive and
tumorigenic activity in BCSCs.
A, Cell proliferation of ERþ-BCSCs and
TN-BCSCs treated with medium or
IL4DM up to 72 hours. B, Fold increase
of ERþ-BCSCs and TN-BCSCs colony
number treated with medium alone
(medium), ADSCs-CM, IL4, ADSCs-CM
in combination with IL4DM, or
IL4þIL4DM. C, Percentage of invading
BCSCs pretreated with IL4DM for 24
hours and subsequently exposed to
ADSCs-CM or IL4 for another 48 hours.
After the treatment, cells were
monitored for their invasive capacity up
to 48 hours. Data represented in ﬁgures
are mean  SD of three independent
experiments using two different
ERþ-BCSCs (pt #4 and pt #18) and two
TN-BCSCs (pt #10 and pt #30).
D, Size of tumors generated by
subcutaneous injection of 4  103 ERþ-
BCSCs or TN-BCSCs pretreated with
medium or IL4 for 24 hours. Mice were
then treated intraperitoneally with
vehicle or IL4DM from week 1 (arrows)
toweek 11. Miceweremonitoredup to 12
weeks. Data are mean  SD of two
subcutaneously injected BCSC lines
for each molecular subtype (n¼ 4 mice
per condition indicated).  , P < 0.01;
 , P < 0.001; NS, nonsigniﬁcant.
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Figure 3.
IL4DM prevents the activation of MAPK pathway. A, Representative ﬂow cytometry analysis of IMC, CD44, and CD24 on TN-BCSCs (pt #30) treated as
indicated for 72 hours. Red dots, double positive cells. B, Immunoblot analysis for DUSP4 of ERþ-BCSCs (pt #18) and TN-BCSCs (pt #30) treated as shown
at the indicated time points. Red box, the time point selected for the further experiments. b-Actin was used as loading control. C–E,Western blot analysis for P-MEK,
MEK, P-ERK, ERK at 45 minutes and for RAS and DUSP4 at 24 hours of ERþ-BCSCs (pt #18) and TN-BCSCs (pt #30) exposed to the indicated treatment. b-Actin
was used as loading control. F. Immunoblot analysis for P-NF-kB and NF-kB of ERþ-BCSCs (pt #18) and TN-BCSCs (pt #30) treated with the indicated agents
for 45 minutes. b-Actin was used as loading control. G,Western blot analysis for P-NF-kB and NF-kB of cells treated as indicated for 45 minutes. H, Immunoblot
analysis for DUSP4 of cells as in G exposed to the indicated treatment for 24 hours. I, Percentage of cell death in cells exposed to ADSCs-CM in combination
with IL4DM and FulvestrantþBKM120 (FulvþBKM120) for ERþ-BCSCs or DocetaxelþBKM120 (DTXþBKM120) for TN-BCSCs at 48 hours. J, Cell death percentage of
cells exposed to IL4 in combinationwith IL4DMand treatedwith antitumoral drugs as in I at the indicated timepoints. Bars representmean SDof three independent
experiments performed with two ERþ-BCSC (pt #4 and pt #18) and two TN-BCSC (pt #10 and pt #30) lines.  , P < 0.05; , P < 0.001; NS, nonsigniﬁcant.
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inhibitors, such as BKM120, in both ERa-negative and -positive
breast cancers (39, 40).
IL4DM in combination with BKM120 and the ERa inhibitor,
fulvestrant (Fulv), for ERþ-BCSCs, or the chemotherapeutic com-
pound docetaxel (DTX), for TNBC subtype, in presence of micro-
environmental cytokines present in the ADSCs-CM, signiﬁcantly
potentiated cell death induced by treatment alone in both ERþ-
and TN-BCSCs, reaching from 40% to 80% (Fig. 3I).
To determine the speciﬁc contribution of IL4 in mediating the
refractoriness to therapy, we exposed BCSCs to the combination
of IL4DMwith the indicated anticancer compounds inpresence of
IL4. Although ERþ-BCSCs exposed to fulvestrant plus BKM120
(FulvþBKM120) did not beneﬁt from the addition to the treat-
ment of IL4DM (Fig. 3J), the latter signiﬁcantly increased the
efﬁcacy of docetaxel plus BKM120 (DTXþBKM120) in TN-BCSCs
at both 24 and 48 hours in the presence or absence of IL4 (Fig. 3J).
These data suggest that the inhibition of IL4 achieves only a partial
response in ERþ-BCSC model due to their extreme sensitivity to
fulvestrant and BKM120, whereas enhances drug efﬁcacy in TNBC
model.
DUSP4 reduces proliferation, invasion, and metastatic
potential of BCSCs
To assess the role of DUSP4 with regard to tumorigenic and
metastatic potential, we stably knocked-down DUSP4
(shDUSP4) in ERþ-BCSCs and MCF7 cells and ectopically
expressed it (DUSP4) in TN-BCSCs and SUM159 cells (Fig. 4A;
Supplementary Fig. S4A–S4C). shDUSP4 provoked a slight
increase in ERþ-BCSC proliferation, which was delayed in TN-
BCSCs overexpressing DUSP4 (Fig. 4B). The analysis of the
invasion assay revealed a potent capability of ERþ-BCSCs har-
boring shDUSP4 to invade the Matrigel in response to the che-
moattractant human serum AB. The ectopic expression of DUSP4
curtailed the invasive potential of TN-BCSCs (Fig. 4C). Moreover,
the knockdown of DUSP4 led to an enrichment in cells able to
form large colonies, whereas their reduction was dictated by
DUSP4 ectopic expression (Fig. 4D).
In accordance with already published data, DUSP4 knock-
down, in ERþ-BCSCs, increased the CD44þ/CD24/CD90 com-
partment, conversely TN-BCSCs, ectopically overexpressing
DUSP4, showed a signiﬁcant decrease of this cell fraction (Fig.
4E; Supplementary Fig. S4DandS4E) by themodulationofMAPK
pathway activation (Fig. 4F; Supplementary Fig. S4F; ref. 9).
Likewise, shDUSP4 in MCF7 cells and DUSP4 overexpression in
SUM159 cells, respectively, enhanced or decreased the activation
of MEK, ERK, and P38 MAPKs (Supplementary Fig. S4G).
By modulating EMT effectors and molecules, which control
breast cancer invasion, P38 has been implicated in multiple steps
of the metastatic process (41). Thus, we reasoned that DUSP4
could be involved in the metastatic dissemination of BCSCs. In
vivo imaging analysis of cells transduced with luciferase showed
that shDUSP4 rendered ERþ-BCSCs able to colonize the liver and
the lung when injected in the tail vein of NOD/SCID mice (Fig.
4G). Conversely, TN-BCSCs overexpressing DUSP4 lost their
metastatic potential (Fig. 4H).Collectively, theseﬁndings conﬁrm
the tumor suppressor role of DUSP4 and unveil a novel role in
inhibiting metastasis.
IL4 favors a more permissive microenvironment
We subsequently evaluated the clinical relevance of IL4 and
DUSP4 in breast cancer patients by interrogating a publically
available database (PROGgeneV2—PanCancer PrognosticsData-
base-GSE10893-GPL887).High expression of IL4 and low expres-
sion levels of DUSP4 resulted to be associated with a decreased
relapse-free survival of patients affected bybreast cancer (HR2.36;
95% CI, 1.15–4.85; P ¼ 0.019; Fig. 5A). IL4 biological main
function relies on the modulation of immune response (42). We
investigated whether adipose tissue, aided by the inﬁltrating T
lymphocytes, could foster a protumorigenic microenvironment.
Tumor cells escape from the cytotoxic activity of CD8þ cells
through the expression of PD-L1, which by binding to its receptor,
PD-1, promotes the apoptosis of cytotoxic T cells (43). IL4DM
markedly diminished the expression of PD-1 on the surface of
activated cytotoxic CD8þ T cells, as compared with its control
(medium) and regardless of the presence of IL4 (Fig. 5B; Supple-
mentary Fig. S5A and S5B). We found that the treatment with IL4
reduced the percentage (of about 15% vs. medium) of activated
cytotoxic CD8þ T cells expressing IFNg . Although IL4DM alone
did not alter T-cell activation, it was notably able to counteract the
effect of IL4, restoring the number of cytotoxic T cells expressing
IFNg (Fig. 5C; Supplementary Fig. S5B). As ERþ- and TN-BCSCs
express PD-L1 (Supplementary Fig. S5C), we hypothesize that
IL4DM could potentially limit the activation of the PD-1 pathway
by reducing the number of cytotoxic PD-1/CD8þ T-cell compart-
ment. These phenomena suggest the existence of a negative
DUSP4 feedback loop that inhibits the MAPK pathway, as well
as the production of cytokines involved in the priming of micro-
environment that fuels cancer progression (Fig. 5D).
Discussion
Here, we provided evidence that BCSCs with a metastatic
propensity express high levels of IL4 along with a downregula-
tion of DUSP4. The latter is conﬁrmed by the inverse correla-
tion between relapse-free survival of breast cancer patients and
IL4 expression. Targeting inﬂammatory mediators in breast
cancer has pointed out appealing endpoints in vitro and in
preclinical models (31, 44). Notwithstanding the ongoing
development of innovative therapeutic agents that block
inﬂammatory cytokines released by tumor microenvironment
and involved in the progression of breast cancer, nowadays the
clinical use of these therapies does not show improvement in
patient outcome (45). On the basis of our previous ﬁndings in
colorectal cancer (6), we here investigated the IL4-mediated
mechanism that regulates the tumorigenic and metastatic
potential of BCSCs.
Targeting IL4 signaling depleted the tumorigenic and meta-
static CD44þ/CD24 cell fraction, thus delaying the prolifer-
ation and invasion capability of BCSCs through the inhibition
of MEK, ERK, and RAS activity. Notably, ERþ-BCSCs expressed
elevated levels of IL4Ra and were promoted to produce IL4
following microenvironmental cytokine stimuli, although to a
lesser extent than TN-BCSCs. Our data indicated that nonmeta-
static ERþ-BCSCs, under tumor microenvironmental inﬂuence,
acquire an invasive phenotype by strengthening IL4 signaling
activity, which is overcome by the blockade of IL4Ra with
IL4DM.
We observed that blocking IL4 signaling, by IL4DM, increases
the expression of DUSP4 concomitantly with the downregulation
of RAS–MAPK pathway. It has recently been demonstrated that in
physiologic conditions, the activation ofMAPK promotes DUSP4
expression, which in turn suppresses ERK, ensuring breast cell
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Figure 4.
DUSP4 hampers the metastatic potential of BCSCs. A, Western blot analysis for DUSP4 of ERþ- BCSCs (pt #18) exposed to medium alone and transduced with
scramble (Scr) and short hairpin DUSP4 (shDUSP4) and TN-BCSCs (pt #30) transduced with empty vector (EV) and DUSP4 synthetic gene (DUSP4). b-Actin was
used as loading control. B, Cell proliferation of cells transduced as in A. C, Percentage of invading cells as described in A. D, Percentage of colony forming
efﬁciency of cells as inA. E, Percentage of CD44high/CD24low positivity of cells treated as in A by ﬂow cytometry analysis. Data are expressed as mean SD of three
independent experiments using two different ERþ-BCSC (pt #4 and pt #18) and two TN-BCSC (pt #10 and pt #30) lines. F, Immunoblot analysis of P-MEK,
MEK, P-ERK, ERK, P-P38, P38 of cells transduced as inA. b-Actin was used as loading control. G and H, In vivowhole-body imaging analysis of mice tail vein injected
with cells transduced with scramble (Scr) and shDUSP4 (shDUSP4) for ERþ-BCSCs and with empty vector (EV) and DUSP4 synthetic gene (DUSP4) for TN-BCSCs.
Yellow dashed ellipse outlines the area of metastasis used for photons count. Data shown are mean  SD of two BCSC lines for each molecular subtype
injected into the tail vein of three mice for each indicated condition.  , P < 0.05;  , P < 0.01;  , P < 0.001.
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turnover. Nevertheless, loss of DUSP4 and its methylation lead to
an aberrant cell proliferation inbasal-like breast cancers (9, 10). In
addition, the activation of NF-kB signaling plays a crucial role in
downregulating the expression levels of DUSP4 in endothelial
cells (46). Strikingly, our data revealed thatDUSP4 is inhibited by
NF-kB activation in an IL4-dependent manner.
Figure 5.
IL4 contributes to the protumorigenic
microenvironment. A, Relapse-free
survival Kaplan–Meier curves
according to IL4/DUSP4 gene
expression ratio in breast cancer
patients.B, Flow cytometry analysis of
PD-1 and its IMC on PBMCs gated for
CD8 positivity (CD8þ T cells).
Activated PBMCs (Activated) refers to
cells exposed to anti-CD3 in
combination with anti-CD28 mAbs for
4 days. Activated cells were then
treated, for additional 4 days, with
medium (medium), IL4 (IL4), IL4DM
(IL4DM), or IL4 in combination with
IL4DM (IL4þIL4DM). Resting PBMCs
(Resting) represent nonactivated cells
cultured in presence of medium alone.
C, Representative ﬂow cytometry
analysis of IFNg on resting and
activated CD8þ T cells treated as
in B. D, Schematic model illustrating
IL4 signaling in breast cancer cells.
ADSCs and CD4þ T helper type
2 lymphocytes (LTh2) secrete IL4 into
the tumor microenvironment. IL4
binding to its cognate receptor, IL4RII,
on breast cancer cells triggers the
activation of RAS–MAPK pathway,
which promotes cancer stemness and
is in turn blocked by DUSP4.
Concurrently, IL4-mediated NF-kB
activation cooperates in the blockage
of DUSP4. Antagonizing IL4Ra, with
IL4DM, inhibits IL4 signaling in cancer
cells and favors cytotoxic CD8þ LT
activation.
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Compelling data indicate that P38 and ERK activation pro-
motes cancer cell dormancy, allowing their survival in a hostile
microenvironment. In addition, P38 induces EMT awakening
cancer cells from dormancy (41, 47). The overexpression of
DUSP4 potently impaired ERK and P38MAPK pathway, prevent-
ing the intrinsic metastatic capability of BCSCs.
Within tumor microenvironment, aside from ADSCs, inﬁltrat-
ing CD4þ Th2 lymphocytes are the other main source of IL4 (42).
IL4 mediates the switching of CD4þ Th1 cells to CD4
þ Th2 cells
affecting their innate antitumor immunity (42). Although the
activation of IL4/STAT6 signal boosts both the tumorigenic and
metastatic activity of breast cancer cells, its loss exerts an antitu-
mor activity through the activation of CD8þ T cells, in a CD4þ LTh
cell-independent manner (19, 48). Although the role of Th2
cytokines in cancer is still contradictory and context dependent
(49), we here demonstrated that targeting IL4 pathway fostered
the cytotoxicity of CD8þ T cells, by increasing intracellular IFNg
content and decreasing their PD-1 expression, expression that is
related with a shorter overall survival in epithelial-originated
cancer patients (50).
Finally, our ﬁndings propose the targeting of IL4 signaling as a
powerful approach in reducing tumor burden and metastatic
colonization. Several commercially available compounds that
block IL4 signaling are presently being utilized in the treatment
of asthma and some have already been tested in clinical trials as
anticancer agents (8). Their administration, in combination with
other novel more effective therapies such as MEK, ERK, and PI3K
inhibitors, warrants further investigation to establish their effec-
tive doses and efﬁcacy.
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